Plant Sterol Against Endometriosis

May 7, 2026

Targeting senescence-associated PAK4 signaling may open new therapeutic directions in endometriosis.

Key Points

Highlights:

Subsets of endometrial lesions that are high in cellular senescence are more aggressive.
PAK4 promotes senescence and drives the progression of lesions.
Stigmasterol effectively suppresses the expression of PAK4, therefore offering promise as a therapeutic agent in senescence-driven pathologies in endometriosis.

Importance:

This study provides mechanistic insight into how cellular senescence may contribute to aggressive lesion behavior and immune dysregulation in endometriosis while identifying PAK4 as a potential therapeutic target.

What’s done here:

Researchers combined transcriptomic analyses of multiple GEO datasets with clinical endometriosis samples, primary cell experiments, and mouse models to investigate senescence-associated heterogeneity in endometriosis.
Functional experiments evaluated the role of the PAK4/AKT signaling axis in lesion progression and macrophage polarization.
The therapeutic potential of stigmasterol was assessed both in vitro and in vivo.

Key results:

There was obvious heterogeneity in cellular senescence between ectopic endometrial lesions.
PAK4 was consistently upregulated in cells with high senescence.
Senescence induced the expression of PAK4, which increased the phosphorylation of AKT, thereby activating the PI3K/AKT signaling pathway and increasing senescence further.
The senescence-PAK4-AKT positive feedback loop leads the lesions to become aggressive and M2 macrophages to be polarized.
PAK4 silencing led to a reduction in cellular senescence and lesion invasiveness and inhibited immune remodeling.
Stigmasterol effectively reduced PAK4 expression, disrupted the senescence-AKT feedback loop, and inhibited cellular senescence and invasion, as well as M2 polarization.

Strengths and Limitations:

Strengths are the integration of bioinformatics analyses, human clinical samples, primary cell experiments, and animal models, together with mechanistic evaluation of the senescence–PAK4–AKT signaling axis and its effects on immune remodeling.
Limitations are the relatively small number of human samples, incomplete clarification of downstream mechanisms linking PAK4 to macrophage polarization, and the preclinical nature and pharmacokinetic limitations of stigmasterol.

From the Editor-in-Chief – EndoNews

"This study advances the evolving concept that endometriosis cannot be understood solely as ectopic tissue implantation, but rather as a dynamic pathological process shaped by cellular senescence, immune remodeling, and lesion-specific microenvironmental heterogeneity. The identification of a senescence-enriched subtype associated with increased invasiveness and M2 macrophage polarization adds an important mechanistic layer to current models of disease progression. Particularly noteworthy is the proposed PAK4–AKT signaling circuit, which links senescence-associated pathways with aggressive lesion behavior and immunomodulation.

Equally important, the study moves beyond descriptive molecular profiling by integrating bioinformatics, primary human tissues, functional cellular experiments, and in vivo models. The demonstration that stigmasterol can disrupt this senescence-associated signaling loop provides an intriguing translational dimension, although its clinical applicability remains far from established.

At the same time, caution is necessary. Endometriosis is biologically and histopathologically heterogeneous, and the proposed senescence-driven subtype requires broader validation in larger human cohorts and across different lesion types. Moreover, whether senescence represents a driver of disease progression or a secondary adaptive response remains incompletely resolved. Nonetheless, this work contributes meaningful mechanistic insight into how senescence-associated immune and signaling pathways may participate in the pathological evolution of endometriosis and opens a potentially important direction for future therapeutic investigation."

Lay Summary

Endometriosis may include an aggressive, immunomodulatory subtype driven by a cellular senescence–PAK4–AKT signaling circuit, according to a new study published in Aging Cell by Jingchun Liu and colleagues from Wuhan University.

The researchers also identified the natural plant sterol stigmasterol as a promising senescence-targeting agent for experimental endometriosis.

Using genomic datasets, patient-derived tissues, primary cell cultures, and mouse models, the investigators identified marked heterogeneity in senescence among ectopic endometriotic lesions. Senescence-enriched lesions demonstrated more aggressive behavior and increased immune remodeling characterized by M2 macrophage polarization. The study showed that PAK4 was consistently upregulated in senescent cells and interacted with AKT, enhancing AKT phosphorylation and activating the PI3K/AKT signaling pathway. This senescence–PAK4–AKT positive feedback loop appeared to further amplify lesion aggressiveness and immune dysregulation.

Importantly, silencing PAK4 reduced cellular senescence, decreased lesion invasiveness, and attenuated immune remodeling. The researchers further demonstrated that stigmasterol effectively reduced PAK4 expression, disrupted the senescence-associated feedback loop, and inhibited senescence, invasion, and M2 macrophage polarization in experimental models.

Although the findings remain preclinical and require further validation before clinical application, the study provides new mechanistic insight into senescence-associated pathological processes in endometriosis and suggests that targeting the senescence–PAK4 axis may represent a future therapeutic strategy.